Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)
ADC ID
DRG0LESGU
ADC Name
Her3-ADC-33 (DAR4)
Synonyms
Her3 ADC 33 (DAR4)
   Click to Show/Hide
Organization
Suzhou Medilink Therapeutics Ltd.
Drug Status
Investigative
Indication
In total 2 Indication(s)
Colon cancer [ICD11:2B90]
Investigative
Lung cancer [ICD11:2C25]
Investigative
Drug-to-Antibody Ratio
5.6
Structure
Antibody Name
Anti-Her3 mAb 202-2-1
  Antibody Info 
Antigen Name
Receptor tyrosine-protein kinase erbB-3 (ERBB3)
  Antigen Info 
Payload Name
Undisclosed
Linker Name
Her3-ADC-33(DAR4) linker
General Information of The Activity Data Related to This ADC
Revealed Based on the Cell Line Data
Click To Hide/Show 1 Activity Data Related to This Level
Standard Type Value Units Cell Line Disease Model
Half Maximal Effective Concentration (EC50) 
50.77
ug/mL
NCI-H358 cells
Minimally invasive lung adenocarcinoma
Full List of Activity Data of This Antibody-drug Conjugate
Revealed Based on the Cell Line Data
Click To Hide/Show 1 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Effective Concentration (EC50) 50.77 ug/mL Positive HER3 expression (HER3 +++/++)
Method Description
Conjugate in various concentrations was added to cells in a 96 well plate at 1,000 cells per well in 100 pL in complete RPMI medium.
In Vitro Model Minimally invasive lung adenocarcinoma NCI-H358 cells CVCL_1559
References
Ref 1 Bioactive substance conjugate, preparation method therefor and use thereof; 2022-08-18.

If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.